A new cut of Phase 2 data on PepGen’s beleaguered oligonucleotide therapy for a genetic nerve and muscle disease has shown disappointing efficacy compared with analysts’ expectations.
The therapy, known as PGN-EDODM1, is intended to …
Welcome back to Endpoints Weekly! They say March comes in like a lion and out like a lamb, but two pharma giants made a roar
Trump signs his pharma tariffs executive order, which won’t affect most large pharma groups but could deal a hefty blow to smaller companies.
OpenLoop Health, a startup powering telehealth companies, has acquired food-as-medicine startup Season Health, OpenLoop confirmed to Endpoints News. The company declined to share the terms
President Donald Trump has signed an executive order confirming that drug products that come from a subset of countries and manufacturers will face 100% tariffs
An ambitious Vancouver startup is trying to ensure the next big diabetes breakthrough retains its ties to Canada, unlike the insulin developers of a century
A new cut of Phase 2 data on PepGen’s beleaguered oligonucleotide therapy for a genetic nerve and muscle disease has shown disappointing efficacy compared with analysts’ expectations.
The therapy, known as PGN-EDODM1, is intended to …